1 Study Coverage 1.1 JAK Inhibitor Based Cancer Drug Product Introduction 1.2 Global JAK Inhibitor Based Cancer Drug Outlook 2017 VS 2022 VS 2028 1.2.1 Global JAK Inhibitor Based Cancer Drug Sales in US$ Million for the Year 2017-2028 1.2.2 Global JAK Inhibitor Based Cancer Drug Sales in Volume for the Year 2017-2028 1.3 United States JAK Inhibitor Based Cancer Drug Outlook 2017 VS 2022 VS 2028 1.3.1 United States JAK Inhibitor Based Cancer Drug Sales in US$ Million for the Year 2017-2028 1.3.2 United States JAK Inhibitor Based Cancer Drug Sales in Volume for the Year 2017-2028 1.4 JAK Inhibitor Based Cancer Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4.1 The Market Share of United States JAK Inhibitor Based Cancer Drug in Global, 2017 VS 2022 VS 2028 1.4.2 The Growth Rate of JAK Inhibitor Based Cancer Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.5 JAK Inhibitor Based Cancer Drug Market Dynamics 1.5.1 JAK Inhibitor Based Cancer Drug Industry Trends 1.5.2 JAK Inhibitor Based Cancer Drug Market Drivers 1.5.3 JAK Inhibitor Based Cancer Drug Market Challenges 1.5.4 JAK Inhibitor Based Cancer Drug Market Restraints 1.6 Study Objectives 1.7 Years Considered 2 Market by Type 2.1 JAK Inhibitor Based Cancer Drug Market Segment by Type 2.1.1 Tofacitinib 2.1.2 Ruxolitinib 2.1.3 Baricitinib 2.2 Global JAK Inhibitor Based Cancer Drug Market Size by Type 2.2.1 Global JAK Inhibitor Based Cancer Drug Sales in Value, by Type (2017, 2022 & 2028) 2.2.2 Global JAK Inhibitor Based Cancer Drug Sales in Volume, by Type (2017, 2022 & 2028) 2.2.3 Global JAK Inhibitor Based Cancer Drug Average Selling Price (ASP) by Type (2017, 2022 & 2028) 2.3 United States JAK Inhibitor Based Cancer Drug Market Size by Type 2.3.1 United States JAK Inhibitor Based Cancer Drug Sales in Value, by Type (2017, 2022 & 2028) 2.3.2 United States JAK Inhibitor Based Cancer Drug Sales in Volume, by Type (2017, 2022 & 2028) 2.3.3 United States JAK Inhibitor Based Cancer Drug Average Selling Price (ASP) by Type (2017, 2022 & 2028) 3 Market by Application 3.1 JAK Inhibitor Based Cancer Drug Market Segment by Application 3.1.1 Rheumatoid Arthritis (RA) 3.1.2 Polycythemia Vera (PCV) 3.1.3 Myelofibrosis (MF) 3.2 Global JAK Inhibitor Based Cancer Drug Market Size by Application 3.2.1 Global JAK Inhibitor Based Cancer Drug Sales in Value, by Application (2017, 2022 & 2028) 3.2.2 Global JAK Inhibitor Based Cancer Drug Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 Global JAK Inhibitor Based Cancer Drug Average Selling Price (ASP) by Application (2017, 2022 & 2028) 3.3 United States JAK Inhibitor Based Cancer Drug Market Size by Application 3.3.1 United States JAK Inhibitor Based Cancer Drug Sales in Value, by Application (2017, 2022 & 2028) 3.3.2 United States JAK Inhibitor Based Cancer Drug Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 United States JAK Inhibitor Based Cancer Drug Average Selling Price (ASP) by Application (2017, 2022 & 2028) 4 Global JAK Inhibitor Based Cancer Drug Competitor Landscape by Company 4.1 Global JAK Inhibitor Based Cancer Drug Market Size by Company 4.1.1 Top Global JAK Inhibitor Based Cancer Drug Manufacturers Ranked by Revenue (2021) 4.1.2 Global JAK Inhibitor Based Cancer Drug Revenue by Manufacturer (2017-2022) 4.1.3 Global JAK Inhibitor Based Cancer Drug Sales by Manufacturer (2017-2022) 4.1.4 Global JAK Inhibitor Based Cancer Drug Price by Manufacturer (2017-2022) 4.2 Global JAK Inhibitor Based Cancer Drug Concentration Ratio (CR) 4.2.1 JAK Inhibitor Based Cancer Drug Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Manufacturers of JAK Inhibitor Based Cancer Drug in 2021 4.2.3 Global JAK Inhibitor Based Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global JAK Inhibitor Based Cancer Drug Manufacturing Base Distribution, Product Type 4.3.1 Global JAK Inhibitor Based Cancer Drug Manufacturers, Headquarters and Distribution of Producing Region 4.3.2 Manufacturers JAK Inhibitor Based Cancer Drug Product Type 4.3.3 Date of International Manufacturers Enter into JAK Inhibitor Based Cancer Drug Market 4.4 Manufacturers Mergers & Acquisitions, Expansion Plans 4.5 United States JAK Inhibitor Based Cancer Drug Market Size by Company 4.5.1 Top JAK Inhibitor Based Cancer Drug Players in United States, Ranked by Revenue (2021) 4.5.2 United States JAK Inhibitor Based Cancer Drug Revenue by Players (2020, 2021 & 2022) 4.5.3 United States JAK Inhibitor Based Cancer Drug Sales by Players (2020, 2021 & 2022) 5 Global JAK Inhibitor Based Cancer Drug Market Size by Region 5.1 Global JAK Inhibitor Based Cancer Drug Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global JAK Inhibitor Based Cancer Drug Market Size in Volume by Region (2017-2028) 5.2.1 Global JAK Inhibitor Based Cancer Drug Sales in Volume by Region: 2017-2022 5.2.2 Global JAK Inhibitor Based Cancer Drug Sales in Volume Forecast by Region (2023-2028) 5.3 Global JAK Inhibitor Based Cancer Drug Market Size in Value by Region (2017-2028) 5.3.1 Global JAK Inhibitor Based Cancer Drug Sales in Value by Region: 2017-2022 5.3.2 Global JAK Inhibitor Based Cancer Drug Sales in Value by Region: 2023-2028 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America JAK Inhibitor Based Cancer Drug Market Size YoY Growth 2017-2028 6.1.2 North America JAK Inhibitor Based Cancer Drug Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific JAK Inhibitor Based Cancer Drug Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific JAK Inhibitor Based Cancer Drug Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe JAK Inhibitor Based Cancer Drug Market Size YoY Growth 2017-2028 6.3.2 Europe JAK Inhibitor Based Cancer Drug Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America JAK Inhibitor Based Cancer Drug Market Size YoY Growth 2017-2028 6.4.2 Latin America JAK Inhibitor Based Cancer Drug Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa JAK Inhibitor Based Cancer Drug Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa JAK Inhibitor Based Cancer Drug Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Pfizer 7.1.1 Pfizer Corporation Information 7.1.2 Pfizer Description and Business Overview 7.1.3 Pfizer JAK Inhibitor Based Cancer Drug Sales, Revenue and Gross Margin (2017-2022) 7.1.4 Pfizer JAK Inhibitor Based Cancer Drug Products Offered 7.1.5 Pfizer Recent Development 7.2 Incyte 7.2.1 Incyte Corporation Information 7.2.2 Incyte Description and Business Overview 7.2.3 Incyte JAK Inhibitor Based Cancer Drug Sales, Revenue and Gross Margin (2017-2022) 7.2.4 Incyte JAK Inhibitor Based Cancer Drug Products Offered 7.2.5 Incyte Recent Development 7.3 Novartis 7.3.1 Novartis Corporation Information 7.3.2 Novartis Description and Business Overview 7.3.3 Novartis JAK Inhibitor Based Cancer Drug Sales, Revenue and Gross Margin (2017-2022) 7.3.4 Novartis JAK Inhibitor Based Cancer Drug Products Offered 7.3.5 Novartis Recent Development 7.4 Eli Lilly 7.4.1 Eli Lilly Corporation Information 7.4.2 Eli Lilly Description and Business Overview 7.4.3 Eli Lilly JAK Inhibitor Based Cancer Drug Sales, Revenue and Gross Margin (2017-2022) 7.4.4 Eli Lilly JAK Inhibitor Based Cancer Drug Products Offered 7.4.5 Eli Lilly Recent Development 8 Industry Chain and Sales Channels Analysis 8.1 JAK Inhibitor Based Cancer Drug Industry Chain Analysis 8.2 JAK Inhibitor Based Cancer Drug Key Raw Materials 8.2.1 Key Raw Materials 8.2.2 JAK Inhibitor Based Cancer Drug Distributors 8.3 JAK Inhibitor Based Cancer Drug Production Mode & Process 8.4 JAK Inhibitor Based Cancer Drug Sales and Marketing 8.4.1 JAK Inhibitor Based Cancer Drug Sales Channels 8.4.2 JAK Inhibitor Based Cancer Drug Distributors 8.5 JAK Inhibitor Based Cancer Drug Customers 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer

List of Tables Table 1. JAK Inhibitor Based Cancer Drug CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028 Table 2. JAK Inhibitor Based Cancer Drug Market Trends Table 3. JAK Inhibitor Based Cancer Drug Market Drivers Table 4. JAK Inhibitor Based Cancer Drug Market Challenges Table 5. JAK Inhibitor Based Cancer Drug Market Restraints Table 6. Global JAK Inhibitor Based Cancer Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States JAK Inhibitor Based Cancer Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global JAK Inhibitor Based Cancer Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States JAK Inhibitor Based Cancer Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top JAK Inhibitor Based Cancer Drug Manufacturers in Global Market, Ranking by Revenue (2021) Table 11. Global JAK Inhibitor Based Cancer Drug Revenue by Manufacturer, (US$ Million), 2017-2022 Table 12. Global JAK Inhibitor Based Cancer Drug Revenue Share by Manufacturer, 2017-2022 Table 13. Global JAK Inhibitor Based Cancer Drug Sales by Manufacturer, (K Units), 2017-2022 Table 14. Global JAK Inhibitor Based Cancer Drug Sales Share by Manufacturer, 2017-2022 Table 15. Global JAK Inhibitor Based Cancer Drug Price by Manufacturer (2017-2022) & (US$/Unit) Table 16. Global JAK Inhibitor Based Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 17. Global JAK Inhibitor Based Cancer Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in JAK Inhibitor Based Cancer Drug as of 2021) Table 18. Top Players of JAK Inhibitor Based Cancer Drug in Global Market, Headquarters and Distribution of Producing Region Table 19. Manufacturers JAK Inhibitor Based Cancer Drug Product Type Table 20. Date of International Manufacturers Enter into JAK Inhibitor Based Cancer Drug Market Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans Table 22. Top JAK Inhibitor Based Cancer Drug Players in United States Market, Ranking by Revenue (2021) Table 23. United States JAK Inhibitor Based Cancer Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 24. United States JAK Inhibitor Based Cancer Drug Revenue Share by Players, 2020, 2021 & 2022 Table 25. United States JAK Inhibitor Based Cancer Drug Sales by Players, (K Units), 2020, 2021 & 2022 Table 26. United States JAK Inhibitor Based Cancer Drug Sales Share by Players, 2020, 2021 & 2022 Table 27. Global JAK Inhibitor Based Cancer Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 28. Global JAK Inhibitor Based Cancer Drug Sales in Volume by Region (2017-2022) & (K Units) Table 29. Global JAK Inhibitor Based Cancer Drug Sales in Volume Forecast by Region (2023-2028) & (K Units) Table 30. Global JAK Inhibitor Based Cancer Drug Sales in Value by Region (2017-2022) & (US$ Million) Table 31. Global JAK Inhibitor Based Cancer Drug Sales in Value Forecast by Region (2023-2028) & (US$ Million) Table 32. North America JAK Inhibitor Based Cancer Drug Sales in Volume by Country (2017-2028) & (K Units) Table 33. North America JAK Inhibitor Based Cancer Drug Sales in Value by Country (2017-2028) & (US$ Million) Table 34. Asia Pacific JAK Inhibitor Based Cancer Drug Sales in Volume by Region (2017-2028) & (K Units) Table 35. Asia Pacific JAK Inhibitor Based Cancer Drug Sales in Value by Region (2017-2028) & (US$ Million) Table 36. Europe JAK Inhibitor Based Cancer Drug Sales in Volume by Country (2017-2028) & (K Units) Table 37. Europe JAK Inhibitor Based Cancer Drug Sales in Value by Country (2017-2028) & (US$ Million) Table 38. Latin America JAK Inhibitor Based Cancer Drug Sales in Volume by Country (2017-2028) & (K Units) Table 39. Latin Americaa JAK Inhibitor Based Cancer Drug Sales in Value by Country (2017-2028) & (US$ Million) Table 40. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales in Volume by Country (2017-2028) & (K Units) Table 41. Middle East and Africa JAK Inhibitor Based Cancer Drug Sales in Value by Country (2017-2028) & (US$ Million) Table 42. Pfizer Corporation Information Table 43. Pfizer Description and Business Overview Table 44. Pfizer JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 45. Pfizer JAK Inhibitor Based Cancer Drug Product Table 46. Pfizer Recent Development Table 47. Incyte Corporation Information Table 48. Incyte Description and Business Overview Table 49. Incyte JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 50. Incyte Product Table 51. Incyte Recent Development Table 52. Novartis Corporation Information Table 53. Novartis Description and Business Overview Table 54. Novartis JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 55. Novartis Product Table 56. Novartis Recent Development Table 57. Eli Lilly Corporation Information Table 58. Eli Lilly Description and Business Overview Table 59. Eli Lilly JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 60. Eli Lilly Product Table 61. Eli Lilly Recent Development Table 62. Key Raw Materials Lists Table 63. Raw Materials Key Suppliers Lists Table 64. JAK Inhibitor Based Cancer Drug Customers List Table 65. JAK Inhibitor Based Cancer Drug Distributors List Table 66. Research Programs/Design for This Report Table 67. Key Data Information from Secondary Sources Table 68. Key Data Information from Primary Sources List of Figures Figure 1. JAK Inhibitor Based Cancer Drug Product Picture Figure 2. Global JAK Inhibitor Based Cancer Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global JAK Inhibitor Based Cancer Drug Market Size 2017-2028 (US$ Million) Figure 4. Global JAK Inhibitor Based Cancer Drug Sales 2017-2028 (K Units) Figure 5. United States JAK Inhibitor Based Cancer Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 6. United States JAK Inhibitor Based Cancer Drug Market Size 2017-2028 (US$ Million) Figure 7. United States JAK Inhibitor Based Cancer Drug Sales 2017-2028 (K Units) Figure 8. United States JAK Inhibitor Based Cancer Drug Market Share in Global, in Value (US$ Million) 2017-2028 Figure 9. United States JAK Inhibitor Based Cancer Drug Market Share in Global, in Volume (K Units) 2017-2028 Figure 10. JAK Inhibitor Based Cancer Drug Report Years Considered Figure 11. Product Picture of Tofacitinib Figure 12. Product Picture of Ruxolitinib Figure 13. Product Picture of Baricitinib Figure 14. Global JAK Inhibitor Based Cancer Drug Market Share by Type in 2022 & 2028 Figure 15. Global JAK Inhibitor Based Cancer Drug Sales in Value by Type (2017-2028) & (US$ Million) Figure 16. Global JAK Inhibitor Based Cancer Drug Sales Market Share in Value by Type (2017-2028) Figure 17. Global JAK Inhibitor Based Cancer Drug Sales by Type (2017-2028) & (K Units) Figure 18. Global JAK Inhibitor Based Cancer Drug Sales Market Share in Volume by Type (2017-2028) Figure 19. Global JAK Inhibitor Based Cancer Drug Price by Type (2017-2028) & (US$/Unit) Figure 20. United States JAK Inhibitor Based Cancer Drug Market Share by Type in 2022 & 2028 Figure 21. United States JAK Inhibitor Based Cancer Drug Sales in Value by Type (2017-2028) & (US$ Million) Figure 22. United States JAK Inhibitor Based Cancer Drug Sales Market Share in Value by Type (2017-2028) Figure 23. United States JAK Inhibitor Based Cancer Drug Sales by Type (2017-2028) & (K Units) Figure 24. United States JAK Inhibitor Based Cancer Drug Sales Market Share in Volume by Type (2017-2028) Figure 25. United States JAK Inhibitor Based Cancer Drug Price by Type (2017-2028) & (US$/Unit) Figure 26. Product Picture of Rheumatoid Arthritis (RA) Figure 27. Product Picture of Polycythemia Vera (PCV) Figure 28. Product Picture of Myelofibrosis (MF) Figure 29. Global JAK Inhibitor Based Cancer Drug Market Share by Application in 2022 & 2028 Figure 30. Global JAK Inhibitor Based Cancer Drug Sales in Value by Application (2017-2028) & (US$ Million) Figure 31. Global JAK Inhibitor Based Cancer Drug Sales Market Share in Value by Application (2017-2028) Figure 32. Global JAK Inhibitor Based Cancer Drug Sales by Application (2017-2028) & (K Units) Figure 33. Global JAK Inhibitor Based Cancer Drug Sales Market Share in Volume by Application (2017-2028) Figure 34. Global JAK Inhibitor Based Cancer Drug Price by Application (2017-2028) & (US$/Unit) Figure 35. United States JAK Inhibitor Based Cancer Drug Market Share by Application in 2022 & 2028 Figure 36. United States JAK Inhibitor Based Cancer Drug Sales in Value by Application (2017-2028) & (US$ Million) Figure 37. United States JAK Inhibitor Based Cancer Drug Sales Market Share in Value by Application (2017-2028) Figure 38. United States JAK Inhibitor Based Cancer Drug Sales by Application (2017-2028) & (K Units) Figure 39. United States JAK Inhibitor Based Cancer Drug Sales Market Share in Volume by Application (2017-2028) Figure 40. United States JAK Inhibitor Based Cancer Drug Price by Application (2017-2028) & (US$/Unit) Figure 41. North America JAK Inhibitor Based Cancer Drug Sales in Volume Growth Rate 2017-2028 (K Units) Figure 42. North America JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 43. U.S. JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 44. Canada JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 45. Europe JAK Inhibitor Based Cancer Drug Sales in Volume Growth Rate 2017-2028 (K Units) Figure 46. Europe JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 47. Germany JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 48. France JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 49. U.K. JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 50. Italy JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 51. Russia JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 52. Asia-Pacific JAK Inhibitor Based Cancer Drug Sales in Volume Growth Rate 2017-2028 (K Units) Figure 53. Asia-Pacific JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 54. China JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 55. Japan JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 56. South Korea JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 57. India JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 58. Australia JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 59. Taiwan JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 60. Indonesia JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 61. Thailand JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 62. Malaysia JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 63. Philippines JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 64. Latin America JAK Inhibitor Based Cancer Drug Sales in Volume Growth Rate 2017-2028 (K Units) Figure 65. Latin America JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 66. Mexico JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 67. Brazil JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 68. Argentina JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 69. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales in Volume Growth Rate 2017-2028 (K Units) Figure 70. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 71. Turkey JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 72. Saudi Arabia JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 73. U.A.E JAK Inhibitor Based Cancer Drug Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 74. JAK Inhibitor Based Cancer Drug Value Chain Figure 75. JAK Inhibitor Based Cancer Drug Production Process Figure 76. Channels of Distribution Figure 77. Distributors Profiles Figure 78. Bottom-up and Top-down Approaches for This Report Figure 79. Data Triangulation Figure 80. Key Executives Interviewed

Pfizer Incyte Novartis Eli Lilly